Entity
  • Sareum Ltd

    Created in 2003
  • BETA

    To investigate (B)
    Some signals may appear as inconsistent with a regular activity
  • Social networks

    1,180
  • Activities

  • Technologies

  • Entity types

  • Location

    Langford Arch, London Rd, Pampisford, Cambridge CB22 3FX, UK

    Pampisford

    United Kingdom

  • Employees

    Scale: 2-10

    Estimated: 6

  • Engaged corporates

    0
    0 0
  • Added in Motherbase

    1 year, 4 months ago
Description
  • Value proposition

    Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

    The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

    Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.

    Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

    Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.

    cancer research, oncology, drug discovery, and auto-immune disease

Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Loading...
Loading...
Social network dynamics